Letsou George V, Anand Jatin, Ogburn Erinn, Shah Rohan M, Ganapathy Anand V, Cohn William E, Loor Gabriel, Frazier O H
Tex Heart Inst J. 2019 Jun 1;46(3):179-182. doi: 10.14503/THIJ-15-5708. eCollection 2019 Jun.
Driveline infection has been a persistent problem with mechanical cardiac assist devices. The reported incidence of infection has been low in patients who receive a Jarvik 2000 continuous-flow left ventricular assist device when a skull-pedestal driveline exit site is used. We evaluated whether this is also true when a subcostal driveline exit site is used. We reviewed baseline demographic variables, postimplantation vital signs, laboratory values, and culture results in patients who underwent Jarvik 2000 implantation at our center from April 2000 through October 2009, including follow-up through June 2014. All patients had a subcostal driveline exit site. We defined device-related infection as a positive blood or wound culture associated with a medical or surgical device intervention. Event and time-to-event rates were calculated. Eighty-one patients received 89 Jarvik 2000 devices, all as bridges to transplantation. The median support duration was 69 days (interquartile range, 27-153 d; range, 2-2,249 d). Five superficial driveline infections and one incision-site infection occurred (0.002 events per patient-year of support). The median time from pump implantation to onset of driveline infection was 30 days; the incision-related infection occurred at 44 days. The Jarvik 2000 has a low incidence of infection when implanted with use of a subcostal driveline exit site. The incidence of pump infections is particularly low. Using a subcostal driveline exit site may be as effective in preventing infections as using a skull-pedestal driveline exit site. We detail our findings in this report.
对于机械心脏辅助装置而言,经皮导线感染一直是个棘手的问题。有报道称,采用颅骨基座经皮导线出口部位的患者接受Jarvik 2000连续流左心室辅助装置时,感染发生率较低。我们评估了采用肋下经皮导线出口部位时情况是否依然如此。我们回顾了2000年4月至2009年10月在我们中心接受Jarvik 2000植入的患者的基线人口统计学变量、植入后的生命体征、实验室检查值及培养结果,随访至2014年6月。所有患者均采用肋下经皮导线出口部位。我们将与医疗或外科装置干预相关的血培养或伤口培养阳性定义为装置相关感染。计算了事件发生率和事件发生时间率。81例患者接受了89台Jarvik 2000装置,均作为移植过渡治疗。中位支持时间为69天(四分位间距,27 - 153天;范围,2 - 2249天)。发生了5例表浅经皮导线感染和1例切口部位感染(每患者年支持时间的事件发生率为0.002)。从泵植入到经皮导线感染发生的中位时间为30天;切口相关感染发生在44天。采用肋下经皮导线出口部位植入时,Jarvik 2000感染发生率较低。泵感染的发生率尤其低。采用肋下经皮导线出口部位预防感染可能与采用颅骨基座经皮导线出口部位同样有效。我们在本报告中详细阐述了我们的研究结果。